LaSalle St. Investment Advisors LLC Buys Shares of 8,240 AbbVie Inc. $ABBV

LaSalle St. Investment Advisors LLC bought a new position in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 8,240 shares of the company’s stock, valued at approximately $2,073,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp lifted its stake in AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares during the period. Geode Capital Management LLC increased its position in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Bank of America Corp DE increased its position in AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the period. Norges Bank bought a new stake in shares of AbbVie in the 4th quarter valued at about $5,865,055,000. Finally, Capital Research Global Investors lifted its position in shares of AbbVie by 0.7% in the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after purchasing an additional 177,370 shares during the period. Institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for a subcutaneous induction regimen of Skyrizi in adults with moderately to severely active Crohn’s disease. The filing, supported by Phase 3 AFFIRM data, could broaden Skyrizi’s commercial opportunity and help offset longer-term concerns about AbbVie’s product portfolio. Is AbbVie Undervalued As It Expands Skyrizi In Crohns Disease?
• Positive Sentiment: Analysts remain broadly optimistic about ABBV’s outlook despite the stock’s reported underperformance versus healthcare peers over the past year. The aging population is also viewed as a long-term demand driver for AbbVie’s immunology treatments. How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. Investors may look for updates on Skyrizi, Rinvoq and the company’s earnings outlook, but no new financial information was provided in the announcement. AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Trading has been relatively steady as investors await the next earnings update. Recent results provide a supportive backdrop: AbbVie previously exceeded quarterly EPS and revenue expectations, with revenue up year over year. AbbVie Stock Holds Steady as Investors Await the Next Earnings Update
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate for AbbVie, creating a modest headwind for the stock and highlighting the risk that expectations may be difficult to exceed.
• Negative Sentiment: Recent institutional activity was mixed, with Burke & Herbert Bank & Trust selling shares while another manager initiated a position. These 13F changes are historical and have limited near-term significance, but the sale may add slight negative sentiment. Burke and Herbert Bank Sells AbbVie Shares

AbbVie Stock Performance

NYSE:ABBV opened at $256.95 on Tuesday. The company’s 50-day simple moving average is $253.20 and its 200-day simple moving average is $229.16. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a market capitalization of $453.98 billion, a P/E ratio of 72.58, a P/E/G ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business posted $2.97 EPS. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent research reports. Guggenheim increased their price objective on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. upped their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. BMO Capital Markets lifted their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.